AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BioLineRx Ltd.

Proxy Solicitation & Information Statement May 31, 2016

6692_rns_2016-05-31_62ac5f39-8034-4313-9877-dbd43328cfac.pdf

Proxy Solicitation & Information Statement

Open in Viewer

Opens in native device viewer

BIOLINERX LTD.

For the Annual General Meeting of Shareholders to be held on July 5, 2016

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned shareholder of BioLineRx Ltd. (the "Company") hereby appoints Norman Kotler and/or Raziel Fried, and each or either of them, the true and lawful attorney, agent and proxy of the undersigned, with full power of substitution, to vote, as designated below, all of the ordinary shares of the Company which the undersigned is entitled in any capacity to vote at the Annual General Meeting of the shareholders of the Company which will be held at the offices of the Company at Modi'in Technology Park, 2 HaMa'ayan Street, Modi'in 7177871, Israel, on July 5, 2016 at 3:00 p.m. (local time), and all adjournments and postponements thereof.

(CONTINUED AND TO BE SIGNED ON REVERSE SIDE) SEE
REVERSE
SIDE

ANNUAL GENERAL MEETING OF SHAREHOLDERS OF

BIOLINERX LTD.

July 5, 2016

THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED HEREIN.
IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED "FOR" THE PROPOSALS HEREIN.
Please mark your vote for the following resolutions as in this example
X
1. TO RE-ELECT the following nominees to
serve as directors of the Company for the
coming year until the next annual general
meeting of the Company's shareholders or
until their respective successors are duly
elected:
FOR AGAINST ABSTAIN
a.
Aharon Schwartz
b.
Michael Anghel
c.
B.J. Bormann
d.
Raphael Hofstein
e.
Sandra Panem
2. TO APPROVE the grant of options to each
of the director nominees as follows, subject
to each such director's re-election as
a
member of the Board of Directors:
FOR AGAINST ABSTAIN
a. A grant to Aharon Schwartz of options to
purchase 90,000 Ordinary Shares as further
described in the Proxy Statement.
b. A grant to Michael Anghel of options to
purchase 90,000 Ordinary Shares as further
described in the Proxy Statement.
c. A grant to B.J. Bormann of options to
purchase 90,000 Ordinary Shares as further
described in the Proxy Statement.
d. A grant to Raphael Hofstein of options to
purchase 90,000 Ordinary Shares as further
described in the Proxy Statement.
e. A grant to Sandra Panem of options to
purchase 90,000 Ordinary Shares as further
described in the Proxy Statement.
3. TO RE-ELECT Ms. Nurit Benjamini as an
external director for a third three-year term
FOR AGAINST ABSTAIN
commencing on July 6, 2016, and to
approve the grant to her of options to
purchase 90,000 Ordinary Shares, all as
described in the Proxy Statement.
Do you have a "Personal Interest" (as
defined in the Proxy Statement)
with
respect to the subject matter of this
YES NO
proposal? (Please note: if you do not mark
either "Yes" or "No" your shares will not
be voted on Proposal 3)
4. TO RE-ELECT Dr. Avraham Molcho as an
external director for a third three-year term
FOR AGAINST ABSTAIN
commencing on July 6, 2016, and to
approve the grant to him of options to
purchase 90,000 Ordinary Shares, all as
described in the Proxy Statement.
Do you have a "Personal Interest" (as
defined in the Proxy Statement)
with
YES NO
respect to the subject matter of this
proposal? (Please note: if you do not mark
either "Yes" or "No" your shares will not
be voted on Proposal 4)
5(a). TO APPROVE an increase in the annual FOR AGAINST ABSTAIN
salary
of
Dr.
Kinneret
Savitsky,
the
Company's Chief Executive Officer, to NIS
918,000.
Do you have a "Personal Interest" (as
defined in the Proxy Statement) with respect
YES NO
to the subject matter of this proposal?
(Please note: if you do not mark either
"Yes" or "No" your shares will not be
voted on Proposal 5(a))
5(b). TO AUTHORIZE the Board of Directors to
approve the framework for the potential
payment to Dr. Kinneret Savitsky, the
FOR AGAINST ABSTAIN
Company's Chief Executive Officer, of an
annual cash bonus for the fiscal year 2016
and thereafter and of a special cash bonus
from time to
time beginning 2016 and
thereafter, all as described in the Proxy
Statement.
Do you have a "Personal Interest" (as
defined in the Proxy Statement) with respect
YES NO
to the subject matter of this proposal?
(Please note: if you do not mark either
"Yes" or "No" your shares will not be
voted on Proposal 5(b))
5(c) TO APPROVE the grant to Dr. Kinneret
Savitsky, the Company's Chief Executive
Officer, (i) of options to purchase 186,200
Ordinary
Shares
and
(ii)
of
93,100
performance stock units, all as described in
the Proxy Statement.
FOR AGAINST ABSTAIN
Do you have a "Personal Interest"
(as
defined in the Proxy Statement) with respect
to the subject matter of this proposal?
(Please note: if you do not mark either
"Yes" or "No" your shares will not be
voted on Proposal 5(c))
YES NO
Name:
Number of shares:
6. TO APPROVE the amended BioLineRx
Ltd. Compensation Policy for Executives
and Directors in the form attached as Annex
A to the Proxy Statement.
FOR AGAINST ABSTAIN Signature:
Date:
Do you have a "Personal Interest" (as
defined in the Proxy Statement) with respect
to the subject matter of this proposal?
(Please note: if you do not mark either
"Yes" or "No" your shares will not be
voted on Proposal 6)
YES NO NOTE: Please mark date and sign exactly as the
name(s) appear on this proxy. If the signer is a
corporation, please sign the full corporate name by
a
duly
authorized
officer.
Executors,
administrators, trustees, etc. should state their full
title or capacity. Joint owners should each sign.
7. TO REAPPOINT Kesselman & Kesselman,
a
member
of
PricewaterhouseCoopers
International Limited, as the independent
registered public accounting firm
of the
Company for the year ending December 31,
2016 and to authorize the Audit Committee
of the Board of Directors to fix the
FOR AGAINST ABSTAIN
compensation of said auditors in accordance
with the scope and nature of their services.

Talk to a Data Expert

Have a question? We'll get back to you promptly.